文献速递白血病造血干细胞移植与细胞治疗

T细胞充足单倍体相合干细胞移植减弱FLT3-ITD在急性髓系白血病中的预后影响:欧洲血液与骨髓移植学会急性白血病工作组报告

T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Am J Hematol · 2018-03-23

该回顾性多中心注册研究纳入2005至2016年首次完全缓解期接受T细胞充足相关单倍体相合造血干细胞移植且FLT3状态已知的成人急性髓系白血病患者293例,其中FLT3野生型202例、FLT3-ITD突变型91例。多因素分析显示FLT3-ITD组与FLT3野生型组的复发率(HR=1.34,95%CI 0.67-2.7;P=.9)和无白血病生存率(HR=0.99,95%CI 0.62-1.57;P=.9)相当,总生存、非复发死亡和移植物抗宿主病无病/无复发生存未受FLT3-ITD状态显著影响。

要点

  • 在T细胞充足单倍体相合移植中,FLT3-ITD与FLT3野生型的复发率(HR=1.34,95%CI 0.67-2.7;P=.9)和无白血病生存率(HR=0.99,95%CI 0.62-1.57;P=.9)相当。
  • FLT3-ITD状态未显著影响总生存、非复发死亡和移植物抗宿主病无病/无复发生存。
  • 在中危细胞遗传学患者亚组中同样未观察到FLT3-ITD的预后影响。

核心结论

  • 在接受T细胞充足单倍体相合干细胞移植的急性髓系白血病患者中,FLT3-ITD突变可能不保留其预后意义。

研究设计与样本

  • 欧洲血液与骨髓移植学会急性白血病工作组的多中心注册回顾性分析。
  • 纳入2005年至2016年首次完全缓解期接受首次T细胞充足相关单倍体相合造血干细胞移植且FLT3状态已知的成人急性髓系白血病患者293例,其中FLT3野生型202例、FLT3-ITD突变型91例。

主要发现

  • FLT3-ITD患者更可能同时伴有NPM1突变以及处于中危细胞遗传学风险类别。
  • 多因素分析中,FLT3-ITD患者与FLT3野生型患者的复发率(HR=1.34,95%CI 0.67-2.7;P=.9)和无白血病生存率(HR=0.99,95%CI 0.62-1.57;P=.9)相当。
  • 总生存、非复发死亡发生率以及移植物抗宿主病无病/无复发生存未受FLT3-ITD状态显著影响。
  • FLT3-ITD患者从不同供者来源(同胞全合、无关供者、单倍体相合移植)接受移植时,复发和总生存相当。
  • 中危细胞遗传学患者亚组分析同样证实FLT3-ITD无预后影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) patients harboring the FLT3-ITD mutation are considered a high risk patient subset preferentially allocated for allogeneic stem cell transplantation in first remission. Whether FLT3-ITD retains a prognostic role in haploidentical stem cell transplantation (haplo-SCT) is unknown. To analyze the prognostic impact of FLT3-ITD in haplo-SCT, we performed a retrospective analysis of the multicenter registry of the acute leukemia working party of the European Society for Blood and Marrow Transplantation. We included all adult AML patients with known FLT3 status who underwent a first T-cell replete related haplo-HCT in first complete remission from 2005 to 2016. We evaluated 293 patients of whom 202 were FLT3wt and 91 were FLT3-ITD mutated. FLT3-ITD patients were more likely to be NPM1 mutated as well as be in the intermediate risk cytogenetic risk category. In multivariate analysis, patients with FLT3-ITD had comparable rates of relapse incidence [Hazard ratio (HR) = 1.34, confidence interval (CI) 95%, 0.67-2.7; P = .9] and leukemia-free survival (HR = 0.99, CI 95%, 0.62-1.57; P = .9) to those of FLT3wt patients. Overall survival, the incidence of nonrelapse mortality, and graft versus host disease-free/relapse-free survival were not significantly impacted by FLT3-ITD status. Furthermore, relapse and overall survival were comparable between FLT3-ITD patients transplanted from various donor pools, namely matched siblings, unrelated donors, haplo-SCT). Finally, subset analysis of patients with intermediate risk cytogenetics confirmed the absence of a prognostic impact of FLT3-ITD also for this patient segment. In AML patients undergoing T-cell replete haplo-SCT, the FLT3-ITD mutation possibly does not retain its prognostic significance.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Canaani J, Labopin M, Huang XJ, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018. PMID: 29498106. doi:10.1002/ajh.25082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。